• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

用于肿瘤免疫治疗的干扰素基因刺激因子激动剂的研究进展

吉力扬, 郝婧, 王国成, 谢唯佳

吉力扬, 郝婧, 王国成, 谢唯佳. 用于肿瘤免疫治疗的干扰素基因刺激因子激动剂的研究进展[J]. 中国药科大学学报, 2020, 51(1): 1-9. DOI: 10.11665/j.issn.1000-5048.20200101
引用本文: 吉力扬, 郝婧, 王国成, 谢唯佳. 用于肿瘤免疫治疗的干扰素基因刺激因子激动剂的研究进展[J]. 中国药科大学学报, 2020, 51(1): 1-9. DOI: 10.11665/j.issn.1000-5048.20200101
shu
JI Liyang, HAO Jing, WANG Guocheng, XIE Weijia. Research progress on stimulator of interferon genes agonists for cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2020, 51(1): 1-9. DOI: 10.11665/j.issn.1000-5048.20200101
Citation: JI Liyang, HAO Jing, WANG Guocheng, XIE Weijia. Research progress on stimulator of interferon genes agonists for cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2020, 51(1): 1-9. DOI: 10.11665/j.issn.1000-5048.20200101
shu

用于肿瘤免疫治疗的干扰素基因刺激因子激动剂的研究进展

  • 1.

    中国药科大学药物化学教研室

  • 2.

    天士力控股集团有限公司天士力研究院

Research progress on stimulator of interferon genes agonists for cancer immunotherapy

摘要

    摘要
  • 摘要: 肿瘤免疫治疗是近年来肿瘤治疗领域新的研究热点。除了免疫检查点抑制剂以及细胞免疫疗法取得了巨大的成功外，小分子免疫疗法也正受到越来越多的关注。干扰素基因刺激因子(STING)作为参与固有免疫应答的关键信号转导分子，在防御病毒及胞内细菌感染、介导Ⅰ型干扰素产生和调节体内自发性抗肿瘤免疫反应产生过程中发挥重要功能。本文简要介绍了STING信号通路的生物学机制，按结构分类综述了STING激动剂的研究进展，以期为STING激动剂类药物的设计和发现提供参考。
    Abstract: In recent years, tumor immunotherapy has become a new hot spot in the field of cancer treatment. Besides the great success of immunological checkpoint inhibitors and cellular immunotherapy, small molecule immunotherapy has also attracted more and more attention. As a key signal transduction molecule involved in the innate immune response, stimulator of interferon genes plays an important role in defending against viral and intracellular bacterial infections, mediating type I IFN production and regulating the production of spontaneous anti-tumor immune responses in vivo. This paper briefly introduces the biological mechanism of STING signaling pathway and reviews the research progress of STING agonists based on the structural classification, so as to provide some reference for the design and discovery of STING agonist drugs.
    • HTML全文
    • 参考文献(44)
  • [1] Ishikawa H,Ma Z,Barber GN.STING regulates intracellular DNA-mediated,type I interferon-dependentinnate immunity[J].Nature,2009,461(7265):788-792.
    [2] Ma Z,Damania B.The cGAS-STING defense pathway and its counteraction by viruses[J].Cell Host Microbe,2016,19(2):150-158.
    [3] Wang Z,Celis E.STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice[J]. Cancer Immunol Immunother,2015,64(8):1057-1066.
    [4] Tang CA,Zundell JA,Ranatunga S,et al.Agonist-mediated activation of STING induces apoptosis in malignant B CElls[J].Cancer Res,2016,76(8):2137-2152.
    [5] Demaria O, De GA, Coso S, et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity[J].Proc Natl Acad Sci U S A,2015,112(50):15408-15413.
    [6] Ishikawa H,Barber GN.STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling[J].Nature,2008,455(7213):674-678.
    [7] Zheng Y,Xing YL,Cheng XJ,et al.Regulation of innate immunity signaling by STING,a stimulator of interferon genes[J].Prog Biochem Biophys(生物化学与生物物理进展),2013,40(1):5-14.
    [8] Ding L,Ni YH,Hu QG,et al.cGAS-STING:the novel mechanism of cytosolic DNA sensing pathways[J].Prog Biochem Biophys(生物化学与生物物理进展),2014,41(9):830-838.
    [9] Gao P,Ascano M,Zillinger T,et al.Structure-function analysis of STING activation by c[G(2′,5′)pA(3′,5′)p] and targeting by antiviral DMXAA[J].Cell,2013,154(4):748-762.
    [10] Ramanjulu JM,Pesiridis GS,Yang JS,et al.Design of amidobenzimidazole STING receptor agonists with systemic activity[J].Nature,2018,564(7736):439-443.
    [11] Cai X,Chiu YH,Chen ZJ.The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling[J].Mol Cell,2014,54(2):289-296.
    [12] Xiao TS,Fitzgerald KA.The cGAS-STING pathway for DNA sensing[J].Mol Cell,2013,51(2):135-139.
    [13] Shang G,Zhang C,Chen ZJ,et al.Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP-AMP[J].Nature,2019,567(7748):389-393.
    [14] Zhang C,Shang G,Gui X,et al.Structural basis of STING binding with and phosphorylation by TBK1[J].Nature,2019,567(7748):394-398.
    [15] Woo SR,Fuertes MB,Corrales L,et al.STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors[J].Immunity,2014,41(5):830-842.
    [16] Xia T,Konno H,Ahn J,et al.Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis[J].Cell Rep,2016,14(2):282-297.
    [17] Corrales L,Glickman LH,Mcwhirter SM,et al.Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity[J].Cell Rep,2015,11(7):1018-1030.
    [18] Ohkuri T,Ghosh A,Kosaka A,et al.STING contributes to anti-glioma immunity via triggering type-I IFN signals in the tumor microenvironment[J].Cancer Immunol Res,2014,2(S3):1199-1208.
    [19] Yue XH,Ye JQ,Sun LP.Biological functions and related diseases of STATs[J].J China Pharm Univ(中国药科大学学报),2016,47(4):404-411.
    [20] Deng L,Liang H,Xu M,et al.STING-Dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors[J].Immunity,2014,41(5):843-852.
    [21] Burdette DL, Monroe KM, Sotelo-Troha K, et al. STING is a direct innate immune sensor of cyclic di-GMP[J].Nature,2011,478(7370):515-518.
    [22] Kato K, Omura H, Ishitani R, et al. Cyclic GMP-AMP as an endogenous second messenger in innate immune signaling by cytosolic DNA[J].Annu Rev Biochem,2017,86:541-566.
    [23] Berger G,Lawler SE.Novel non-nucleotidic STING agonists for cancer immunotherapy[J].Future Med Chem,2018,10(24):2767-2769.
    [24] Li L,Yin Q,Kuss P,et al.Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs[J].Nat Chem Biol,2014,10(12):1043-1048.
    [25] Corrales L,Gajewski TF.Molecular pathways:targeting the stimulator of interferon genes(STING)in the immunotherapy of cancer[J].Clin Cancer Res,2015,21(21):4774-4779.
    [26] Fu J,Kanne DB,Leong M,et al.STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade[J].Sci Transl Med,2015,7(283):283ra252.
    [27] ESMO 2018 Congress.New clinical findings involving STING agonist as monotherapy and in combination with an anti-PD-1 therapy[EB/OL].(2018-10-20)[2019-01-20] .https://www.mrknewsroom.com/news-release/oncology-newsroom/first-presentation-early-data-mercks-investigational-sting-agonist-mk.
    [28] Truong QT,Cumming JN,Altman MD,et al.Cyclic di-nucleotide compounds as STING agonists:WO,2017027645[P].2017-03-17[2019-01-20] .
    [29] Lim JW,Wu WL,Cumming JN,et al.Cyclic dinucleotide derivatives are STING agonists-useful for treating cell proliferation disorders,such as cancers:WO,2018208667[P].2018-10-16[2019-01-20] .
    [30] Biggadike K,Coe DM,Needham D,et al.Cyclic dinucleotides useful for the treatment of inter alia cancer:WO,2016120305[P].2015-04-15[2019-01-20] .
    [31] Yang JS,Adam M,Clemens J,et al.Preclinical characterization of GSK532,a novel STING agonist with potent anti-tumor activity[J].Clin Res,2018,78(13):5554.
    [32] American Association for Cancer Research(AACR)Special Conference on Tumor Immunology and Immunotherapy.Positive preclinical findings support advancement of SB-11285 into further development as a potential immunotherapeutic agent in cancer[EB/OL].(2016-10-20)[2019-01-20] .https://www.marketwatch.com/press-release/spring-bank-pharmaceuticals-presents-data-on-sting-agonist-sb-11285-at-the-aacr-special-conference-on-tumor-immunology-and-immunotherapy-2016-10-20.
    [33] 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer(SITC 2018).Preclinical characterization of BMS-986301,a differentiated STING agonist with robust antitumor activity as monotherapy or in combination with anti-PD-1[EB/OL].(2018-11-06)[2019-01-20] .https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220479/.
    [34] BrumL JR, Canham S, Kanne DB, et al. Locked nucleic acid cyclic dinucleotide compounds and uses thereof:WO,2018009466[P].2018-01-11[2019-01-20] .
    [35] Carotta S,Fleck M,Oost T,et al.Cyclic dinucleotide compounds:WO,2018060323[P].2018-04-05[2019-01-20] .
    [36] Lioux T,Mauny MA,Lamoureux A,et al.Design,synthesis,and biological evaluation of novel cyclic adenosine-inosine monophosphate(cAIMP)analogs that activate stimulator of interferon genes(STING)[J].J Med Chem,2016,59(22):10253-10267.
    [37] Plowman J,Narayanan VL,Dykes D,et al.Flavone acetic acid:a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice[J].Cancer Treat Rep,1986,70(5):631-635.
    [38] Liu JJ,Ching LM,Goldthorpe M,et al.Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours[J].Cancer Chemother Pharmacol,2007,59(5):661-669.
    [39] Corrales L,Gajewski TF.Molecular pathways:targeting the stimulator of interferon genes(STING)in the immunotherapy of cancer[J].Clin Cancer Res,2015,21(21):4774-4779.
    [40] Lu M,Tyagarajan S,Cash BD,et al.Benzo[b]thiophene compounds as STING agonists:WO,2018067423[P].2018-04-07[2019-01-20] .
    [41] Trotter BW,Kopinja JE,Tse ANC,et al.Combinations of PD-1 antagonists and benzo[b]thiophene STING agonists for cancer treatment:WO,2019027858[P].2019-02-08[2019-01-20] .
    [42] Sali TM, Pryke KM, Jinu A, et al. Characterization of a novel human-specific STING agonist that elicits antiviral activity against emerging alphaviruses[J].PLoS Pathog,2015,11(12):e1005324.
    [43] Kimura Y,Negishi H,Matsuda A,et al.Novel chemical compound SINCRO with dual function in STING-type I interferon and tumor cell death pathways[J].Cancer Sci,2018,109(9):2687-2696.
    [44] Liu B,Tang L,Zhang X,et al.A cell-based high throughput screening assay for the discovery of cGAS-STING pathway agonists[J].Antiviral Res,2017,147:37-46.
    • 相关文章
    • 施引文献(2)

  • 期刊类型引用(2)

    1. 李焱琳，王琪. 干扰素介导肿瘤免疫分子机制的相关研究进展. 临床合理用药. 2025(02): 177-180 . 百度学术
    2. 梅家豪，洪泽，王琛. 靶向cGAS-STING信号通路药物的研究进展. 中国药科大学学报. 2020(03): 249-259 . 本站查看

    其他类型引用(0)

    • 资源附件(0)
计量
  • 文章访问数:  1147
  • HTML全文浏览量:  0
  • PDF下载量:  1570
  • 被引次数: 2
出版历程
  • 刊出日期:  2020-02-24

目录

摘要
HTML全文
    参考文献(44)
    相关文章
    施引文献(2)
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：335805

    x 关闭 永久关闭